Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study

Blood (2018) 132 (Supplement 1): 46.

https://doi.org/10.1182/blood-2018-99-113718

Published: 2018

Journal Articles

B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line

Matheus Sebastian Da Silva, Eliana C Miranda, Marcia Torresan Delamain, MD, Gislaine Oliveira Duarte, MD, Bruna R Vergilio, Ana Beatriz Pascoal Lopes, Jessica CN Vianna, Carmino Antonio De Souza, MD PhD, Erich Vinicius De Paula, MD PhD, Katia B Pagnano, MD

Blood (2018) 132 (Supplement 1): 1749.

https://doi.org/10.1182/blood-2018-99-114036

Published: 2018

Journal Articles

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Negative (ALCL, ALK-): Analysis of 203 Patients Prospectively Registered in the International T-Cell Project

Andrei Shustov, MD, Maria Elena Cabrera, Monica Bellei, MSc, PhD, Young Hyeh Ko, MD, Martina Manni, PhD, Steven M. Horwitz, MD, Carmino Antonio De Souza, MD PhD, John A. Radford, MD, Sabela Bobillo Varela, Maria Virginia Prates, MD, Andrés J M Ferreri, MD, Carlos Chiattone, MD, Michele Spina, MD, Julie M. Vose, MDMBA, Annalisa Chiappella, MD, Daniele Laszlo, MD, Dario Marino, MDPhD, Caterina Stelitano, Massimo Federico, MD

Blood (2017) 130 (Supplement 1): 4071.

https://doi.org/10.1182/blood.V130.Suppl_1.4071.4071

Published: 2017

Journal Articles

Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) — Evaluation of Pioglitazone in Treatment-Free Remission

Katia B Pagnano, MD, Eliana C Miranda, Marcia Torresan Delamain, Gislaine Oliveira Duarte, MD, Bruna Virgilio, Jessica Vianna, Erich Vinicius De Paula, MD PhD, Carmino Antonio De Souza, MD PhD

Blood (2017) 130 (Supplement 1): 1595.

https://doi.org/10.1182/blood.V130.Suppl_1.1595.1595

Published: 2017

Journal Articles

E14a2 and e14a2+e13a2 BCR-ABL Transcripts Are Associated with Earlier Cytogenetic and Molecular Response Rates in CML-CP Treated with Imatinib

Katia B Pagnano, MD, Eliana C Miranda, Fernanda S Seguro, MD, Gustavo HR Magalhaes, MD, Nelma D Clementino, MD, Arthur Moellmann-Coelho, MD, Maryanna N Da Silva, Renato Centrone, MD, Monika Conchon, MD, Jaisson Bortolini, MD, Teresa Cristina Bortolheiro, MD, Valquiria Povoa, Luciana Nardinelli, Carmino Antonio De Souza, MD PhD, Israel Bendit, MD PhD

Blood (2017) 130 (Supplement 1): 1596.

https://doi.org/10.1182/blood.V130.Suppl_1.1596.1596

Published: 2017

Journal Articles

VEGF , VEGFR2 and GSTM1 polymorphisms in Outcome of Multiple Myeloma Patients in the Thalidomide Era

Leisa Lopes-Aguiar, Marcia Torresan Delamain, Angelo Borsarelli Carvalho Brito, Gustavo Jacob Lourenço, Ericka Francislaine Dias Costa, Gislaine Borba Oliveira, Jose Vassallo, Carmino Antônio De Souza, MD PhD, Carmen Silvia Passos Lima

Blood (2016) 128 (22): 4457.

https://doi.org/10.1182/blood.V128.22.4457.4457

Published: 2016

Journal Articles

Influence of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Imatinib 400 Mg

Katia B.B. Pagnano, MD PhD, Eliana Cristina Martins Miranda, PhD, Marcia T Delamain, MD, Gislaine OLIVEIRA Duarte, MD, Erich Vinicius De Paula, MD PhD, Valquiria Povoa, Bruna Rocha Vergilio, Irene Lorand-Metze, MD PhD, Carmino Antônio De Souza, MD PhD

Blood (2016) 128 (22): 1911.

https://doi.org/10.1182/blood.V128.22.1911.1911

Published: 2016

Journal Articles

Clinical Characteristics and Outcome of 104 Patients with Gastric Diffuse B-Cell Non-Hodgkin Lymphoma (DLBCL) a Multicenter Study

Marcia T Delamain, MD, Eliana Cristina Martins Miranda, PhD, Maria Gomes da Silva, MDPhD, Joana Desterro, MD, Merli Francesco, MD, Carlos Chiattone, MD PhD, Stefano Luminari, MD, Katia BB Pagnano, Carmino Antonio De Souza, MD PhD, Massimo Federico

Blood (2015) 126 (23): 5032.

https://doi.org/10.1182/blood.V126.23.5032.5032

Published: 2015

Journal Articles

Collagen Fibers Structure Detected By Second-Harmonic Generation Microscopy: A Potential Prognostic Marker for High-Risk Nodular Sclerosis

Guilherme Rossi Assis de Mendonça, Rodrigo de Andrade Natal, Bruna de Albuquerque Murbach, Marcia Torresan Delamain, MD, Carmino Antônio De Souza, MD PhD, Carlos Lenz Cesar, PhD, Jose Vassallo, MD PhD

Blood (2015) 126 (23): 5000.

https://doi.org/10.1182/blood.V126.23.5000.5000

Published: 2015

Journal Articles

Pre-Transplant Beta2-Microglobulin Is an Independent Biomarker of Acute Graft-Versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant in a Single Institutional Study

Carolina Costa-Lima, MD, Eliana Cristina Martins Miranda, PhD, Marcos Paulo Colella, MD, Francisco José Penteado Aranha, MD PhD, Carmino Antônio De Souza, MD PhD, Afonso Celso Vigorito, MD PhD, Erich Vinicius De Paula, MD PhD

Blood (2015) 126 (23): 3152.

https://doi.org/10.1182/blood.V126.23.3152.3152

Published: 2015

Journal Articles

Association of Bax and Bcl-2 polymorphisms in Aggressiveness and Prognosis of Diffuse Large B-Cell Lymphoma

Angelo Borsarelli Carvalho Brito, Cristiane Oliveira, Marcia Toressan Delamain, MD, Carmino Antonio De Souza, MD PhD, José Vassallo, MD PhD, Carmen Silvia Passos Lima, MD PhD

Blood (2014) 124 (21): 3017.

https://doi.org/10.1182/blood.V124.21.3017.3017

Published: 2014

Journal Articles

VEGF 2578 c>a, a Functional Angiogenic Polymorphism, Is Associated with Aggressiveness and Clinical Outcome of Follicular Lymphoma

Guilherme Rossi Assis de Mendonça, Angelo Borsarelli Carvalho Brito, Rodrigo de Andrade Natal, Marcia T Delamain, MD, Carmino Antonio De Souza, MD PhD, Gisele W. B. Colleoni, MD, José Vassallo, MD PhD, Carmen Silvia Passos Lima, MD PhD

Blood (2014) 124 (21): 3022.

https://doi.org/10.1182/blood.V124.21.3022.3022

Published: 2014

Journal Articles

Clinical Characteristics and Outcome of 41 Patients with Upper GI Diffuse B-Cell Non-Hodgkin Lymphoma. Results of Brazilian-Italy Lymphoma Registry

Marcia T Delamain, MD, Eliana C M Miranda, MD PhD, Merli Francesco, MD, Carlos S Chiattone, MD PhD, Anna Fedina, Stefano Luminari, MD, Carmino Antonio De Souza, MD PhD, Federico Massimo, MD

Blood (2014) 124 (21): 5400.

https://doi.org/10.1182/blood.V124.21.5400.5400

Published: 2014

Journal Articles

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

Timothy P. Hughes, Giuseppe Saglio, Hagop M. Kantarjian, François Guilhot, Dietger Niederwieser, Gianantonio Rosti, Chiaki Nakaseko, Carmino Antonio De Souza, Matt E. Kalaycio, Stephan Meier, Xiaolin Fan, Hans D. Menssen, Richard A. Larson, Andreas Hochhaus

Blood (2014) 123 (9): 1353–1360.

https://doi.org/10.1182/blood-2013-06-510396

Published: 2014

Includes: Supplemental data

Journal Articles

Associations Of VEGF and VEGFR2 Polymorphisms With Increased Risk and Aggressiveness Of Multiple Myeloma

Angelo Borsarelli Carvalho Brito, Leisa Lopes Aguiar, Gislaine Borba Oliveira, MD, Gustavo Jacob Lourenco, PhD, Carmino Antonio De Souza, José Vassallo, MD, PhD, Carmen Silvia Passos Lima, MD, PhD

Blood (2013) 122 (21): 1886.

https://doi.org/10.1182/blood.V122.21.1886.1886

Published: 2013

Journal Articles

Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial

Jorge E. Cortes, MD, Carmino Antonio De Souza, PhD, Jose Luis Lopez, MD, Manuel Ayala, MD, Eduardo Bullorsky, Xiaojun Huang, Sandip Shah, K. Govind Babu, Tomasz Sacha, MD, Israel Bendit, Zhizhou Liang, Tina Owugah, Prasanna Kumar Nidamarthy, Tomasz Szczudlo, Carmen Piccolo, MD, Philipp D. le Coutre, MD

Blood (2013) 122 (21): 95.

https://doi.org/10.1182/blood.V122.21.95.95

Published: 2013

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)

Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Giuseppe Saglio, François Guilhot, Haifa Kathrin Al-Ali, MD, Giantonio Rosti, Chiaki Nakaseko, MD, PhD, Carmino Antonio De Souza, PhD, Charisse Kemp, Xiaolin Fan, PhD, Albert Hoenekopp, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 167.

https://doi.org/10.1182/blood.V120.21.167.167

Published: 2012

Journal Articles

EUTOS Score Is Predictive of Event-Free Survival, but Not for Progression-Free and Overall Survival in Patients with Early Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib: A Single Institution Experience

Katia B. Pagnano, MD, Irene Lorand-Metze, MD, PhD, Eliana C M Miranda, Vagner O Duarte, Marcia T Delamain, MD, Gislaine O Duarte, MD, Carmino Antonio De Souza, MD, PhD

Blood (2012) 120 (21): 1681.

https://doi.org/10.1182/blood.V120.21.1681.1681

Published: 2012

Journal Articles

Early Assessment of Molecular Response in Chronic Myeloid Leukemia Patients On Dasatinib After Imatinib Failure Identify Patients with Poor Cytogenetic and Molecular Responses

Katia B. Pagnano, MD, Beatriz F Ribeiro, Eliana C M Miranda, Marcia T Delamain, MD, Carmino Antonio De Souza, PhD, Gislaine O Duarte, MD, Bruna Vergilio, Dulcinéia Martins Albuquerque, BSc, MSc, PhD, Andrey dos Santos, PhD, Anderson Tavares, Irene Lorand-Metze, MD, PhD

Blood (2012) 120 (21): 3787.

https://doi.org/10.1182/blood.V120.21.3787.3787

Published: 2012

Journal Articles

The Utilization of NET Promoter System As a Blood Supply Management Strategy

Gustavo De Carvalho Duarte, MD, Erich V de Paula, MD, PhD, Francisco J P Aranha, MD, PhD, Gislaine Borba Oliveira, MD, Afonso Celso Vigorito, MD, PhD, Carmino Antonio De Souza, MD, PhD, José Francisco Marques, PhD

Blood (2012) 120 (21): 4378.

https://doi.org/10.1182/blood.V120.21.4378.4378

Published: 2012

NARROW

Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study

B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Negative (ALCL, ALK-): Analysis of 203 Patients Prospectively Registered in the International T-Cell Project

Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) — Evaluation of Pioglitazone in Treatment-Free Remission

E14a2 and e14a2+e13a2 BCR-ABL Transcripts Are Associated with Earlier Cytogenetic and Molecular Response Rates in CML-CP Treated with Imatinib

VEGF , VEGFR2 and GSTM1 polymorphisms in Outcome of Multiple Myeloma Patients in the Thalidomide Era

Influence of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Imatinib 400 Mg

Clinical Characteristics and Outcome of 104 Patients with Gastric Diffuse B-Cell Non-Hodgkin Lymphoma (DLBCL) a Multicenter Study

Collagen Fibers Structure Detected By Second-Harmonic Generation Microscopy: A Potential Prognostic Marker for High-Risk Nodular Sclerosis

Pre-Transplant Beta2-Microglobulin Is an Independent Biomarker of Acute Graft-Versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant in a Single Institutional Study

Association of Bax and Bcl-2 polymorphisms in Aggressiveness and Prognosis of Diffuse Large B-Cell Lymphoma

VEGF 2578 c>a, a Functional Angiogenic Polymorphism, Is Associated with Aggressiveness and Clinical Outcome of Follicular Lymphoma

Clinical Characteristics and Outcome of 41 Patients with Upper GI Diffuse B-Cell Non-Hodgkin Lymphoma. Results of Brazilian-Italy Lymphoma Registry

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

Associations Of VEGF and VEGFR2 Polymorphisms With Increased Risk and Aggressiveness Of Multiple Myeloma

Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)

EUTOS Score Is Predictive of Event-Free Survival, but Not for Progression-Free and Overall Survival in Patients with Early Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib: A Single Institution Experience

Early Assessment of Molecular Response in Chronic Myeloid Leukemia Patients On Dasatinib After Imatinib Failure Identify Patients with Poor Cytogenetic and Molecular Responses

The Utilization of NET Promoter System As a Blood Supply Management Strategy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only